MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Cytek Biosciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

5.39 -3.92

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.38

Max

5.48

Pagrindiniai rodikliai

By Trading Economics

Pajamos

105K

-5.5M

Pardavimai

6.7M

52M

Pelnas, tenkantis vienai akcijai

-0

Pelno marža

-10.476

Darbuotojai

692

EBITDA

6.4M

-4.2M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+10.97% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-26

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

240M

742M

Ankstesnė atidarymo kaina

9.31

Ankstesnė uždarymo kaina

5.39

Naujienos nuotaikos

By Acuity

17%

83%

18 / 361 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Cytek Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-16 23:29; UTC

Karštos akcijos

Stocks to Watch: Atossa Therapeutics, Union Pacific

2026-01-16 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

2026-01-16 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

2026-01-16 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

2026-01-16 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Auto & Transport Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-16 21:48; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

2026-01-16 21:41; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

2026-01-16 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

2026-01-16 20:44; UTC

Uždarbis

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

2026-01-16 20:42; UTC

Rinkos pokalbiai

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

2026-01-16 20:28; UTC

Rinkos pokalbiai

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

2026-01-16 19:12; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

2026-01-16 18:53; UTC

Rinkos pokalbiai

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

2026-01-16 18:41; UTC

Rinkos pokalbiai

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

2026-01-16 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-16 17:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-16 17:03; UTC

Rinkos pokalbiai

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026-01-16 16:32; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

2026-01-16 16:20; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Cytek Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

10.97% į viršų

12 mėnesių prognozė

Vidutinis 6.17 USD  10.97%

Aukščiausias 7.5 USD

Žemiausias 5 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cytek Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

3.7 / 3.8Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

18 / 361 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat